Hippocampal Subfields Volume: Another Hint of the Continuum Between CAA and AD ?

Le résumé fourni par la source

OBJECTIVE: This study investigates whether cerebral amyloid angiopathy (CAA) patients with Alzheimer's disease (AD)-like CSF profile exhibit radiological features characteristic of AD, specifically reduced hippocampal and amygdala volumes. METHODS: From a database of 162 probable CAA cases (Boston 2.0 criteria) at the Fondazione IRCCS Istituto Neurologico Carlo Besta, 44 patients underwent CSF analysis (Aβ42, Aβ40, and p-Tau181) and brain MRI with volumetric T1 sequences. Participants with CSF levels of Aβ42 < 640 pg/mL and p-Tau181 > 56.5 pg/mL were classified as CAA/AD+; otherwise, as CAA/AD-. Hippocampal and amygdala volumes were assessed using volBrain software, and statistical analyses included t-tests and Mann-Whitney U tests. RESULTS: CAA/AD+ patients (n = 22) were older than CAA/AD- (median age: 73 vs. 67 years, p = 0.006). No significant differences were observed in total hippocampal or amygdala volumes. However, Cornu Ammonis 2-3 (CA2-CA3) hippocampal subfield volume and its ratio to total intracranial volume were significantly lower in CAA/AD+ patients (0.29 vs. 0.35, p = 0.015; 0.02 vs. 0.03, p = 0.011). DISCUSSION: We found that CA2-CA3 atrophy, potentially linked to tau pathology, was a distinctive feature in our CAA/AD+ cohort. While total hippocampal and amygdala volumes did not differentiate these groups, CA2-CA3 volume may serve as a radiological marker for identifying biological overlaps between CAA and AD. Future studies should validate these findings and explore their implications for neurodegenerative diseases. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04204642.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.